Treatment of prolonged seizure with diazepam nasal spray: An exploratory post hoc cohort analysis
Epilepsy & Behavior · 2024-10 · 159 · 109987
DOI: 10.1016/j.yebeh.2024.109987 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy & Behavior, 2024-10. Verfasst von Randa Jarrar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Phoenix Children's Hospital, 1919 E Thomas Rd Ambulatory Building, Floor 3, Phoenix, AZ 85016, USA. Electronic address: rjar…. Hauptthemen laut MEDLINE: Diazepam, Seizures, Nasal Sprays, Anticonvulsants. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Benzodiazepines are used in first-line rescue therapy as immediate-use seizure medication for the treatment of seizure clusters and prolonged seizures. Their use varies across clinical practices and conditions, and they can be used promptly when indicated. Clinical studies have demonstrated seizure termination within 2 min when diazepam nasal spray is used to treat seizure clusters within 5 min, but the response when treating longer duration seizures in a cluster remains to be characterized. OBJECTIVE: To describe and assess timing and dosing of diazepam nasal spray in the subset of prolonged seizures within seizure clusters in a larger dataset of all treated seizure clusters collected during a long-term safety study of diazepam nasal spray. METHODS: Using timing data recorded in seizure diaries, this post hoc analysis and associated sensitivity analyses focused on prolonged seizures treated 5 to 15 min after the seizure start. Measures included time to treatment administration and time to seizure termination. Second-dose data were used as a proxy for effectiveness. RESULTS: In this group of seizure clusters treated 5 to 15 min after seizure start, median time drug administration was 6 min after seizure start, median time from drug administration to seizure termination was 7 min, and median overall seizure duration was 15 min. Sensitivity analyses by age, epilepsy type, and high seizure frequency confirmed this pattern. Use of a second dose occurred in 9.3 % of episodes, with the majority of second doses administered ≤ 4 h after the first dose. Safety results from the overall study showed 82.2 % of patients had ≥ 1 treatment-emergent adverse event (TEAE) irrespective of relationship to treatment, during a mean participation of ∼ 1.5 years. In addition, 30.7 % patients had a serious TEAE, and 18.4 % had TEAEs deemed at least possibly related to the study drug, none of which were serious. No events of cardiorespiratory depression were reported. CONCLUSIONS: Although immediate use of diazepam nasal spray (within 5 min) resulted in quicker seizure termination, a treatment delay of 5 to 15 min still produced rapid termination of the seizure cluster with high first-dose effectiveness and an overall acceptable safety profile. These findings suggest that diazepam nasal spray maintains effectiveness in prolonged seizures within a cluster with delayed treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Phoenix Children's Hospital, 1919 E Thomas Rd Ambulatory Building, Floor 3, Phoenix, AZ 85016, USA. Electronic address: rjarrar@phoenixchildrens.com.
- Department of Neurology, Geffen School of Medicine, University of California Los Angeles, Los Angeles 710 Westwood Plaza, Los Angeles, CA 90095-1769, USA. Electronic address: jstern@ucla.edu.
- Department of Neurology, Ohio State University, Wexner Medical Center 395 W. 12th Ave., 7th Floor, Columbus, OH 43210, USA. Electronic address: dbecker8@gmail.com.
- CSD Biostatistics, Inc., 1005 W. Soft Wind Place, Oro Valley, AZ 85737, USA. Electronic address: csdbiostat@gmail.com.
- Clinical Development and Medical Affairs, Neurelis, Inc., 3430 Carmel Mountain Rd Suite 300, San Diego, CA 92121, USA; Center for Molecular Biology and Biotechnology, Charles E. Schmidt College of Science, Florida Atlan…
- Clinical Development and Medical Affairs, Neurelis, Inc., 3430 Carmel Mountain Rd Suite 300, San Diego, CA 92121, USA; Department of Family Medicine, John A. Burns School of Medicine, University of Hawaii, 651 Ilalo St,…
Zitieren
APA
Jarrar, R., Stern, J. M., Becker, D. A., Davis, C., Rabinowicz, A. L., & Carrazana, E. (2024). Treatment of prolonged seizure with diazepam nasal spray: An exploratory post hoc cohort analysis. Epilepsy & Behavior, 159, 109987. https://doi.org/10.1016/j.yebeh.2024.109987
Vancouver
Jarrar R, Stern JM, Becker DA, Davis C, Rabinowicz AL, Carrazana E. Treatment of prolonged seizure with diazepam nasal spray: An exploratory post hoc cohort analysis. Epilepsy & Behavior. 2024;159:109987. doi:10.1016/j.yebeh.2024.109987
BibTeX
@article{Jarrar2024,
author = {Jarrar, Randa and Stern, John M and Becker, Danielle A and Davis, Charles and Rabinowicz, Adrian L and Carrazana, Enrique},
title = {Treatment of prolonged seizure with diazepam nasal spray: An exploratory post hoc cohort analysis},
journal = {Epilepsy & Behavior},
year = {2024},
volume = {159},
pages = {109987},
doi = {10.1016/j.yebeh.2024.109987}
}
EUVIMED